| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1694 | |
| Phytochemical name or plant extracts | Erythrina corallodendron essential oil | |
| PMID | 31490383 | |
| Literature evidence | The findings of this study suggest that the essential oil of E. corallodendron leaves may merit further investigation as a potential clinical or adjuvant drug for treating breast cancer migration and invasion. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Essential oil | |
| Source of phytochemicals or plant Extracts | Erythrina corallodendron | |
| Geographical availability | Dominican Republic, Haiti, Jamaica, Leeward Is., Puerto Rico, Windward Is. | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Lung cancer, Leukemia | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | Inhibition effect is mediated by suppression of the EMT process through the slug/snail pathways. | |
| IC50 | 1.09+/-0.08 μL/mL against MDA-MB-231, (1.47+/-0.09)μL/mL for MCF-7 cell | |
| Potency | The findings of this study suggest that the essential oil of E. corallodendron leaves may merit further investigation as a potential clinical or adjuvant drug for treating breast cancer migration and invasion. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, HMLE | |
| Additional information | Researchers have reported that linalool(a predominant compound of ECEO) could be used as a treatment for oral cancers by acting through the PI3K/Akt pathway. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:316421-2 | |
| Safety | NA |